

18 June 2025



**Eden Research plc**  
("Eden" or "the Company")

**AGM statement**

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, will hold its Annual General Meeting today at 11:00 am BST at Cavendish's office: 1 Bartholomew Close, London EC1A 7BL.

**At the meeting, Eden's Chairman, Lykele van der Broek, will make the following statement:**

Over the past year, Eden has made tremendous strides in its journey towards becoming a leader in the biological crop protection industry.

With revenues up 34% year on year, we are confident in the trajectory we are setting for the Company, which is supported by the growing demand for our innovative products in a changing agricultural landscape. We have experienced a year of key regulatory milestones and product development advancements, which will help continue to drive revenue in the short and medium term and support us in reaching the point of cashflow positivity, which will be a significant milestone for the business.

One of the major highlights of the year was the regulatory authorisation of Mevalone® for Botrytis and powdery mildew in California, the largest wine-producing region in the US, by far. The state's agricultural sector has a strong focus on sustainability, and the approval of our biofungicide product has opened up substantial commercial opportunities for Eden in the region. We anticipate a meaningful increase in sales in the coming years as a result, once certain label restrictions have been removed.

In addition, the authorisation of Mevalone® for use on a significant number of new crops and fungal pathogens in Spain further expands its addressable market, commercial potential, and overall appeal to growers. This approval is already yielding results, with our team seeing early benefits in 2025.

We were also excited to receive regulatory approval for Novellus+ in Mexico. This new formulation of Mevalone® represents an enhanced version of our flagship fungicide, offering stronger appeal in certain important markets. The approval opens new revenue opportunities for Eden, particularly in horticulture, where we see strong demand for sustainable crop protection solutions.

Another key achievement in 2024 was the continuation of the emergency use authorisation for Ecovelex in Italy. This product has been a key driver of revenue for Eden, with meaningful sales recorded towards the end of the year. The ongoing regulatory progress towards full authorisation in the foreseeable future is a major step in unlocking the product's full potential across Europe. With full approval, Ecovelex will be able to address the European market, as a whole, and we expect it to become an even more significant contributor to Eden's revenue growth in the years ahead.

Our wider product pipeline remains robust, with several exciting products under development, including our first bioinsecticide, which targets key pests such as aphids, spider mites, and whiteflies.

Eden and its partners completed over 140 field trials for our insecticide in 2024, a testament to the growing interest in Eden's innovative products. As we approach the commercialisation phase, we are engaging with several potential distribution partners and expect to conclude negotiations as soon as practicable. The insecticide market holds tremendous potential for Eden, especially as traditional chemical products come under increasing regulatory scrutiny due to environmental and health concerns. Eden's insecticide represents an exciting opportunity to fill this gap with a sustainable and effective solution for farmers. We anticipate regulatory submissions in the US and Europe in due course, with the potential for first sales in the US within the next two years, subject to regulatory approvals.

We are also working on two additional product candidates: a second biofungicide targeting late blight and a bioinsecticide aimed at controlling Lepidoptera pests. These products represent significant commercial opportunities for Eden and will help to further diversify our product offering and revenue streams.

The growth of our team in 2024 has been an important part of our progress. We have made several key hires in strategic areas, including sales, regulatory affairs, supply chain, and marketing and product management. These additions will help us scale our business and accelerate the commercialisation of our pipeline as we expand into new markets, products and applications.

At the Board level, we were also pleased to welcome Derek McAllan as a new Non-Executive Director and Chairman of the Audit Committee, who brings valuable experience in advising growth companies, particularly in the life sciences sector. We look forward to his contributions as we continue to grow our business.

The agricultural industry continues to evolve, and Eden is at the forefront of this transformation. Biopesticides are increasingly seen as a key solution to the environmental and health challenges posed by some conventional pesticides. As a result, we are witnessing a surge of interest in Eden's products from growers seeking effective and sustainable alternatives. Despite the ongoing challenges in the industry, such as the slow pace of regulatory approval, supply chain disruptions, and price volatility

of agricultural produce, we are optimistic about the future. The continued demand for biopesticides and the increasing regulatory support for sustainable farming practices provide a strong tailwind for Eden's growth.

Looking ahead, we remain optimistic about Eden's prospects. Our revenue growth, regulatory achievements, product development progress, and commercial partnerships position us well for the future. I would like to take this opportunity to thank our shareholders for their continued support and the entire Eden team for their tireless efforts. Together, we are building a sustainable future for Eden and for the agricultural industry.

-- ENDS --

For further information contact:

**Eden Research plc**

Sean Smith  
Alex Abrey

[www.edenresearch.com](http://www.edenresearch.com)  
01285 359 555

**Cavendish Capital Markets Limited**  
**(Nominated advisor and joint broker)**  
Giles Balleny / George Lawson (corporate finance)  
Harriet Ward (corporate broking)  
Michael Johnson (sales)

020 7220 0500

**Oberon Capital (Joint broker)**

Nick Lovering  
Mike Seabrook  
Adam Pollock

020 3179 5300

**Hawthorn Advisors (Financial PR)**  
Victoria Ainsworth

[eden@hawthornadvisors.com](mailto:eden@hawthornadvisors.com)

**Notes to Editors:**

**Eden Research** is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

Based on plant-derived active ingredients, **Mevalone®** is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

**Novellus®+** is an evolution of Mevalone, allowing improved rates in the field, high levels of efficacy and a broader list of targets.

**Cedroz™** is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's seed treatment product, **Ecovelex™** was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

Eden's **Sustaine®** encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease of use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange **Green Economy Mark** in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

For more information about Eden, please visit: [www.edenresearch.com](http://www.edenresearch.com). You can also follow Eden's latest developments via its social media channels: [X \(Twitter\)](#) and [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGMFRMATMTJBBPA